This work presents an innovative cross-linking procedure to keratoconus treatment, a corneal disease. It includes the development of an ultraviolet controlled emission portable device based on LED source and a new formulation of a photosensitive drug called riboflavin. This new formulation improves drug administration by its transepithelial property. The UV reaction with riboflavin in corneal tissue leads to a modification of corneal collagen fibers, turning them more rigid and denser, and consequently restraining the advance of the disease. We present the control procedures to maintain UV output power stable up to 45mw/cm 2 , the optical architecture that leads to a homogeneous UV spot and the new formulation of Riboflavin.
INTRODUCTION
Corneal collagen cross-linking (CXL) has introduced a promising alternative to Keratoconus treatment¹. The keratoconus is an ectatic, non-inflammatory, progressive disease that causes corneal tissue structure weakening, leading to a conical shaped cornea, therefore loss of visual acuity (progressive myopic visual impairment and irregular astigmatism). Statistically, the incidence of this disease is between 20 and 230 per 100.000². In recent years, cross-linking has been considered an alternative method to keratoconus stagnation, and can avoid cornea transplantation or introduction of contact lenses. Wollensak et al. have established the conventional treatment protocol, which is divided in two stages: Riboflavin administration and UV light exposure. This technique consists in administration of photosensitive substance called Riboflavin (solution of vitamin B2) to enhance the UV absorption in the cornea. The application of riboflavin drops is done every two minutes for 30 minutes (pre-soak time). The epithelium, membrane that covers the cornea, is removed in order to allow penetration of Riboflavin into the cornea in a region called stroma. After this, cornea is subjected to a low power density of UV, 3 mW/cm 2 for 30 minutes, resulting in a total dose of 5.4 J/cm 2 . Interaction between riboflavin and UV light induces the formation of more bonds among adjacent collagen molecules, which modifies corneal structure by making it more rigid and denser. Therefore, the result is a less susceptible cornea to shape modification, avoiding the keratoconus advance. cells. Additionally, Sliney 6 made a study of safety in accelerated cross-linking procedure offered by Avedro 7 relating corneal absorption dose of UV with depth of corneal tissue. In accelerated procedure, the pre-soak time duration, time that corneal is under Riboflavin presence before UV exposure, is shorter than conventional procedure, resulting in quite same dose of UV absorption in region nearby endothelium. It leads to conclusion that accelerated procedure is as safe as the conventional procedure.
The equipment presented in this work was developed to attend the standard and accelerated well-known established protocols applied in CXL Keratoconus treatment. It is a portable type A ultraviolet emission device with peak wavelength at 365 nm and output power density up to 45 mW/cm 2 . This power let the procedure duration shorter, and can be theoretically performed in 2 minutes. It is composed of a UV illumination source attached to a special set of lenses and mirrors to project the light on the patient's cornea. Such light projection has uniform power distribution and homogeneous light density in the illuminated area. In addition, a red light source is coupled into the system to indicate to the doctor the focus of the optical system. An electronic system will be responsible to control light emission and is composed of a microcontroller circuit connected to a power control loop with feedback and a current driver. The critical point of this system is to maintain a constant light output for treatment and achieve a high level of optical efficiency capable to provide 45 mW / cm 2 at the output. This system results in constant output power and in uniform power distribution, with less than 10% of variation in both cases.
Additionally, Anselmo Oliveira presents new studies intending to eliminate the necessity to remove the corneal epithelium to permit Riboflavin penetration in cornea. He proposes the development of a solution that consists in the incorporation of the hydrophilic riboflavin in a system with nanometric dimensions, as the nanoemulsion, which combines the properties of bioadhesion and permeability increasing, to allow the riboflavin permeates through the epidermis of the cornea and fixes in stroma. Although he presents good results, the pre-soak time duration was too long for treatment purpose. A new formulation of the nanostrctured riboflavin was created and is presented in this work, and the main goal is to make possible the reduction of penetration time duration in CLX treatment procedure.
Finally, this work is divided as follows: section 1 is the introduction; the UV LED system device and the nanoemulsion of riboflavin are in section 2; the results obtained with the created control system and the formulation of new riboflavin are in section 3; conclusions are in section 4.
METHODOLOGY

Accelerated Cross-linking
The technique proposed by this work is already being applied by international companies such as Avedro 7 and doctors as Ronald R. Krueger 4 . Accelerated cross-linking consists in reducing the time of ultraviolet radiation application by increasing the power dose and keeping the same total treatment energy (5.4 J/cm²). The UV emission device developed in this work has output power enough to reduce the application time up to 2 minutes by setting output power to 45 mW/cm 2 . The procedure consists in three steps. First, scrapes or flaps are made on corneal epithelium to permit riboflavin (photosensitive solution of vitamin B12) to penetrate in internal corneal tissue called stroma. Figure 1 shows the membranes involved on treatment. After some days the epithelium is naturally recomposed. Second, drops of riboflavin are dispensed on corneal surface every 5 minutes during a period of 10 to 30 minutes (time dependent of UV power). This time is called pre-soak time, which is suggested by recent researches to be of 10 minutes using a power of 30 mW/cm² [8] [9] [10] . Third, the cornea is exposed to ultraviolet light (4 minutes irradiation with 30 mW/cm 2 , 365 nm UVA). Additionally, there are no treatment tests with a higher dose, but it is supposed that doctors will come up with new studies using shorter time application, as the new machine developed in this work is able to offer higher power. Furthermore, the procedure will use a new formulation of riboflavin that is based in nanoemulsion platform (riboflavin-5-phosphate), which does not demand removal of the corneal epithelium during pre-soak time. This application is called transepithelial. The advantages of using the accelerated cross-linking in junction with the transepithelial riboflavin are as follow: fast procedure, most patients can be treated; low risk of infection because of epithelium is not removed; painless procedure; quick recover of the patient; the procedure can be performed out of operating room because there is no surgical intervention (low treatment cost). Figure 2 presents the simulation of UV procedure. Figure 2 -A shows the corneal flaccid shape and weak bonds in collagen fibers of the cornea; Figure 2 -B shows the pre-soak procedure, in which drops of riboflavin are dispensed on corneal tissue; Figure 2 -C shows the UV light emission on corneal surface, which is responsible to create more bonds in collagen fibers and make corneal tissue more rigid; Figure 2 -D shows the result of treatment, more bonds were created in cornea tissue, it is more rigid and denser, thus is less susceptible of shape changes (it avoids the advance of keratoconus). 
Optics System
As formerly discussed, treatment requires a homogenized beam to be delivered in order to avoid hot spots which may lead to localized sub-threshold irradiation, causing some areas to become more flaccid then others, which may lead to development of a localized Keratoconus. An UV illumination system was designed based on LED as showed in Figure 3 .
Light from an UV LED with peak wavelength at 365 nm is focused first at surface 1, where a diaphragm is placed to 12 . The e power). It is to enlarge the 
Riboflavin-Nanostructured
The standard protocol of CXL proposed by Wollensak et al.¹ recommends removing the corneal epithelium before treatment to allow the penetration of riboflavin into the stroma. Experimental and clinical research has shown that the intact epithelium does not block the effects of ultraviolet light (UVA) 16 , but reduces the effectiveness of treatment by altering adequate diffusion of riboflavin into the stroma 17 . However, epithelium removal causes risks and can increase the frequency of infections in the cornea, opacity, scars and infiltration [18] [19] [20] . Moreover, it can cause pain, photophobia and delayed visual rehabilitation. In a previous project, Anselmo et al. evaluated the stromal penetration of riboflavin phosphate in nanoemulsion biocompatible formulation, using intact rabbit corneas. Although the absorption of nanoemulsion riboflavin phosphate was similar to the standard technique of cross-linking with epithelium removal, the time of penetration was too large, around 120 minutes 21 .
Among technological possibilities, pharmaceutical formulations based on nanotechnology platform constitute an innovative way to facilitate penetration of riboflavin through the corneal epithelium. The standard riboflavin solution (10 mg riboflavin-5-phosphate / 10 ml 20% dextran T-500) has hydrophilic characteristics which do not allow adequate diffusion through the corneal epithelium. Considering the physico-chemical properties of riboflavin base and riboflavin phosphate, they do not have the ability to permeate into the stroma. Due to lipophilic characteristic of corneal epithelium, riboflavin base interacts with the corneal epithelium and do not properly permeates into the stroma. Moreover, due to the riboflavin phosphate characteristic of hydrophilicity and anionic character, it is repelled from the surface of the cornea and riboflavin do not sufficiently permeate into the stroma. Thus, a technologically feasible delivery system involves incorporation of the hydrophilic riboflavin in a system with nanometric dimensions, as the nanoemulsion, which combines the properties of bioadhesion and permeability increasing, so as to allow the riboflavin to permeate through the corneal epidermis (lipophilic) and secure the stroma (hydrophilic). Thus, the bioadhesive property of the vehicle will allow the hydrophilic riboflavin have an intense contact with the surface of the cornea and increase the permeability of riboflavin. It will allow the passage through corneal tissue, with retention in the stroma, as the corneal endothelium also has lipophilic character. The main goal with this new formulation is to achieve proper concentration of riboflavin in stroma by not demanding hours of pre-soak time.
RESULTS
Control system
The embedded electronic was developed and assembled with all the principles shown earlier ( Figure 5 ) in the UV LED console in order to evaluate the performance of the optics and control system. The embedded control software was developed in the same way as shown in equation 1 to 4. To evaluate the control system process, the LED control system was turned on and output power and LED current wave forms were collected by an oscilloscope. It is possible to analyze the behavior of the LED current and light output power during the transitory and steady-state regime and verify if the control system response time is capable to produce rise time of milliseconds and no oscillations. If the rise-time of the pulse is too long when compared to the pulse duration, the delivery energy will be reduced to values that will not produce the desired therapeutic effects. Due to cross-linking procedure establishment pulse duration of 30 minutes, or accelerated going to 10 minutes, rise time response in milliseconds is fast enough to do not compromise total energy density of treatment. Figure 6 shows three different power responses of the LED control system. Chanel 1 of oscilloscope is the LED current read by precision resistor sensor, and channel 2 is the LED power output read by photodiode. The current relation in the sensor circuit is 23 V / 1 A, and the power relation in photodiode circuit is 0.133 V / 1 mW. Graph A is the power response to a set point value of 5 mW, graph B is the power response to a set point value of 15 mW, and Graph C is the power response to a set point value of 36 mW. The responses are stable, no overshoot (current obeyed a smooth crescent ramp in the initial process), there is short rise time, and less than 10% of steady-state error. This parameter is important because the LED device is a medical equipment, and is supposed to attend IEC 60601-1 and IEC 60602-2-22 standards, which limit LED power output variations up to 20%. Table 1 presents the final LED control system calibration performance, listing main parameters in different output power setting. The measures cover the output power range of the UV LED device. It is clear the linearity of set power to the output power, even though the LED current to power output is non-linear. It proves the effect of the power control loop system. Figure 7 shows the output power by LED current. Maximum power was set to 36 mW because it corresponds to 45 mW/cm 2 with a beam diameter of 10 mm. One interesting point is that the maximum power was achieved by running the LED with 190 mA. It is lower than the recommended work current of 500 mA on datasheet 22 . Then, if new researches demand more power, this device is ready to provide. 
Optical system
The LED radiant flux at maximum output power of cross-linking device, for 187.84 mA, is 169 mW (0.9 mW/mA), data from LED datasheet 22 . It enables to measure the system efficiency (output flux/input flux) taking in account the power losses in the optical system, LED divergence and Joule effect in LED semiconductor. If the system delivers 36 mW @ 187.84 mA, and LED is emitting 169 mW, the efficiency is 21%, which is not an issue, as the LED works in a light current regime to obtain the desired output power. Ellie.
1.00
Orient. 
=13.5%
Beam shape at focus plane is the most important characteristic imposed by the optical system. It has to present a homogeneous power distribution at the illuminated area to create an equal cross-linking effect at the entire corneal tissue. Figure 8 , Figure 9 and Figure 10 present power distribution at focus plane got by beam analyzer Beamage Focus1 of GentecEO. They show that beam area has less than ±10% of power variations at average line of beam power. This work considered the standard applied in lasers (IEC 60601-2-22) for approval beam homogeneity, because it is also applied to high power LED medical devices. Variation less than ±20% of average power is acceptable to lasers devices. There are some not continuous points at image because of dead pixels on CCD sensor. Figure 10 . UV beam shape at focal plane, spot of 10 mm. Figure 11 shows a picture of the Cross-linking console assembly. The optical system is placed inside a 3D plastic prototype, all optics are mounted inside machined aluminium mounts, electronic circuit and display are connected out of the console prototype. All tests were done using this assembly, which will pass through engineering process to turn into a final product to be manufactured soon by Opto Eletronica SA. Figure 12 shows the optical system of UV light and the red color crosshair aiming beam to guide doctor in aiming the beam on patient's cornea. Figure 13 shows the design of the device that will be produced and its commercial name is Opto XLink. 
Cross-linking device
Riboflavin
The base formulation contains riboflavin phosphate 1%, soy phosphatidylcholine, nonionic surfactant, cationic surfactant, block copolymer and saline (Table 2 ). For the systems preparation, the samples were irradiated with ultrasound, in sonication tubes for 12 minutes in a batch regime with an irradiation time of 1 minute and 30 seconds, using amplitude 8. The determination of the hydrodynamic diameter and zeta potential were performed using the Zetasizer (Malvern Instruments) equipment 23 . Apparent viscosity measurements were performed with a rheometer 24 .
Regardless of the ratio of lipid, the nanoemulsion showed rheological profile material and thixotropic non-Newtonian, but the viscosity decreases with shear rate. However, the relaxation of the shear rate leads to a viscosity recovery time dependent, which provides a superior viscosity profile at shear return to the initial situation. It was also found that increasing the proportion of the lipid in nanoemulsion resulted viscosity values higher than the lowest concentration ( Figure 14) , although it has not caused changes in the rheological. The maximum values for the zeta potential were about 32.5 and 36.5 mV (Table 3) , and constant concentration of the block copolymer shows excellent stability of the colloidal dispersion. However, these values decrease to about 19 mV by increasing copolymer concentration, and it demonstrates that the PLU adhered on the surface of oil phase droplets, leaving their polyethylene chains exposed on the surface, causing an impediment to the approach of scattered ions in the medium and decreasing the reading surface potential (Table 3) . 
CONCLUSION
The present work showed the implementation of a controlled UVA LED based optical system device and the formulation of a new riboflavin. Equipment and drug are designed to treat especially Keratoconus disease on corneal tissue, the first lens of human eye, by a process called cross-linking. The equipment aimed at accelerating the treatment time by increasing the power density and keeping the well-known energy dose of 5.4 J/cm 2 by reducing exposure time. Additionally, riboflavin is incorporated in a system with nanometric dimensions, nanoemulsion, which combines the properties of bioadhesion and permeability increasing, so as to allow the riboflavin permeate through the corneal epidermis and to be kept in the stroma. This procedure tends to be faster, it has less infection risk, it is a painless procedure and offers a quick recovery to the patient.
The optical system developed proved to be very efficient in delivering a homogeneous power distribution on focus plane. The variations observed are less then ±10% of average flux power, which complies with laser and high power LED standard IEC 60601-2-22. Therefore, the entire treating corneal area will receive the same radiation, resulting in equally collagen fibers bonds enlargement, which arise in a better treatment.
The power control system showed to be very efficient in controlling the LED output power. It has achieved the output power specification of 45 mW/cm 2 at a current below LED limit. The architecture of hardware and software controllers in cascade resulted in increased output power velocity readings, pulse operation in steady-state regime, without overshoot and fast responses. When the UV light output reaches stability, the steady-state error is less than 10%. This rise-time value of 30 milliseconds, in worst case, denotes an insignificant loss of energy during entire treatment that takes minutes, and is perfectly acceptable by laser standard.
The device prototype had excellent performance to guarantee the mechanical distances between the lens involved and stability during the use. Additionally it has a portable and light design, which makes the transportation and set up easy to end user.
The riboflavin-nanostructured was developed and the first quality parameters were measured like zeta potential and rheological parameters. The results showed that the nanoemultion will have good bioadhesion to corneal surface and that it is ready to start the studies in rabbit's corneas. These studies will be carried out in partnership with Unifesp (Universidade Federal de São Paulo), which will receive one XLink prototype and samples of riboflavin to advance with riboflavin development.
